| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84196 |
cas:1884578-27-1 ,Alloc-Val-Ala-PAB-PNP,N-[(2-丙烯-1-基氧基)羰基]-L-缬氨酸-N-[4-[[(4-硝基苯氧基)羰基]氧基]甲基]苯基]-L-丙氨酸酰胺 |
189 |
kx |
2024-12-19 |
| 84197 |
mDPR-Val-Cit-PAB-MMAE(CAS:1491152-26-1) |
165 |
WYQ |
2024-12-19 |
| 84198 |
2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13-tetraoxa-4-azahexadecan-16-oate |
174 |
wyh |
2024-12-19 |
| 84199 |
MC-Val-Cit-PAB-vinblastine(CAS:2055896-92-7) |
159 |
WYQ |
2024-12-19 |
| 84200 |
2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13-tetraoxa-4-azahexadecan-16-oate |
159 |
wyh |
2024-12-19 |
| 84201 |
MC-Val-Cit-PAB-tubulysin5a(CAS:2055896-86-9) |
141 |
WYQ |
2024-12-19 |
| 84202 |
N-芴甲氧羰基-四聚乙二醇-VAL-ALA-PAB, Fmoc-PEG4-Val-Ala-PAB |
190 |
kx |
2024-12-19 |
| 84203 |
MC-Val-Cit-PAB-clindamycin(CAS号:1639793-13-7) |
157 |
WYQ |
2024-12-19 |
| 84204 |
MC-Val-Cit-PAB-carfilzomib,CAS号:2055896-83-6 |
169 |
WYQ |
2024-12-19 |
| 84205 |
叔丁酯-四聚乙二醇-VAL-ALA-PAB,Boc-PEG4-Val-Ala-PAB |
139 |
kx |
2024-12-19 |
| 84206 |
MC-Val-Cit-PAB-Auristatin E,CAS号:2055896-77-8 |
173 |
WYQ |
2024-12-19 |
| 84207 |
MC-Sq-Cit-PAB-Gefitinib(CAS:1941168-63-3) |
240 |
WYQ |
2024-12-19 |
| 84208 |
HS-(CH2)m-(EG)n -N(+)(CH3)2-CH2-COO(-) 聚乙二醇化直链烷烃硫醇 |
169 |
h |
2024-12-19 |
| 84209 |
Mal-PEG4-Val-Ala-PAB,马来酰亚胺-四聚乙二醇-VAL-ALA-PAB |
218 |
kx |
2024-12-19 |
| 84210 |
MC-GGFG-DX8951(CAS:1600418-29-8) |
899 |
WYQ |
2024-12-19 |
| 84211 |
(HO)2-PO-S-(CH2)6-EG2-OH 硫-(2-羟基六烷-1-基)硫代磷酸酯 |
199 |
h |
2024-12-19 |
| 84212 |
Au_55_C11EG4Carboxybetaine 金团簇55-羧基甜菜碱 |
244 |
h |
2024-12-19 |
| 84213 |
(HO)2-PO-S-(CH2)m-COONHS 硫-(2,5-二氧代 - 吡咯烷-1-基氧基羰基)-1-基硫代磷酸 |
204 |
h |
2024-12-19 |
| 84214 |
2529982-76-9,Azido-PEG4-Val-Ala-PAB,叠氮-四聚乙二醇-VAL-ALA-PAB |
185 |
kx |
2024-12-19 |
| 84215 |
Au_12_C11EG6 金团簇12-直链烷烃六聚乙二醇 |
229 |
h |
2024-12-19 |
| 84216 |
cas:863971-17-9 ,MC-Val-Cit-PAB-MMAF,MC-VAL-CIT-PAB-MMAF游离态 |
148 |
kx |
2024-12-19 |
| 84217 |
CF3-(CF2)5-C2-O-C11-Si(OMe)3 巯基-直链烷烃连接氟化硫醇和硅烷 |
194 |
h |
2024-12-19 |
| 84218 |
cas:2353409-69-3 , Mal-PEG8-Val-Cit-PAB-MMAE,马来酰亚胺-八聚乙二醇-VAL-CIT-PAB-MMAE |
178 |
kx |
2024-12-19 |
| 84219 |
cas:2129164-91-4 , DBCO-PEG4-Val-Cit-PAB-MMAE,二苯并环辛炔-四聚乙二醇-VAL-CIT-PAB-MMAE |
241 |
kx |
2024-12-19 |
| 84220 |
MAL-di-EG-Val-Cit-PAB-MMAF,由ADC连接桥(MAL-di-EG-Val-Cit-PAB)和有效的微管蛋白聚合阻断剂(MMAF, Monomethyl auristatin F)组成 |
199 |
WYQ |
2024-12-19 |
| 84221 |
MAL-di-EG-Val-Cit-PAB-MMAE,CAS编号:2746391-62-6 |
212 |
WYQ |
2024-12-19 |
| 84222 |
cas:644981-35-1 , Val-Cit-PAB-MMAE, ADC试剂 |
128 |
kx |
2024-12-19 |
| 84223 |
cas:2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE,抗体药物偶联物(ADC) |
244 |
kx |
2024-12-19 |
| 84224 |
AcLys-PABC-VC-Aur0101(CAS:1438851-17-2) |
176 |
WYQ |
2024-12-19 |
| 84225 |
反式环辛烯-MMAE,TCO-MMAE, ADC试剂 |
249 |
kx |
2024-12-19 |
| 84226 |
Hydrazone-doxorubicin,阿霉素-腙键偶联物 |
308 |
WYQ |
2024-12-19 |
| 84227 |
SPP-DM1(CAS号:452072-20-7)C44H59ClN4O14S2 |
237 |
WYQ |
2024-12-19 |
| 84228 |
氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮),Amino-PEG2-VG-N-Bis(PEG1-azide) |
173 |
kx |
2024-12-19 |
| 84229 |
DOTA-NHS ester,羟基琥珀酰亚胺-四氮杂环十二烷四乙酸(CAS号:170908-81-3) |
192 |
WYQ |
2024-12-19 |
| 84230 |
Maleimido-mono-amide-DOTA(CAS号:1006711-90-5) |
265 |
WYQ |
2024-12-19 |
| 84231 |
cas:2055041-40-0,Azido-PEG1-Val-Cit-PAB-OH,叠氮-一聚乙二醇-VAL-CIT-PAB-羟基 |
132 |
kx |
2024-12-19 |
| 84232 |
MB-VC-MGBA CAS号:932744-62-2 |
215 |
WYQ |
2024-12-19 |
| 84233 |
Anti-GPNMB-VC-MMAE-ADC抗体偶联药物 |
172 |
zyl |
2024-12-19 |
| 84234 |
MA-PEG8-VA-PAB-SG3199,硫醇反应SET™毒素 |
222 |
WYQ |
2024-12-19 |
| 84235 |
cas:1662687-83-3 , Mal-PEG2-Val-Cit-PABA,马来酰亚胺-二聚乙二醇-VAL-CIT-PABA |
146 |
kx |
2024-12-19 |
| 84236 |
Boc-Val-Ala-PAB cas:1884577-99-4 |
206 |
zyl |
2024-12-19 |
| 84237 |
perfluorophenyl 1-(cyclooct-2-ynyloxy)-2-oxo-6,9,12-trioxa-3-azapentadecan-15-oate |
159 |
wyh |
2024-12-19 |
| 84238 |
MA-PEG4-VA-PBD(CAS号:2259318-50-6) |
180 |
WYQ |
2024-12-19 |
| 84239 |
SPDP-Val-Cit-PAB-PNP-ADC抗体偶联药物 |
228 |
zyl |
2024-12-19 |
| 84240 |
cas:1438853-35-0,Mal-PEG3-Val-Cit-PAB-PNP,马来酰亚胺-三聚乙二醇-VAL-CIT-PAB-PNP 酯 |
157 |
kx |
2024-12-19 |